Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis.
- 1 November 1977
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 56 (5) , 889-890
- https://doi.org/10.1161/01.cir.56.5.889
Abstract
Methysergide (Sansert) is known to cause mitral and aortic valvular fibrosis and dysfunction, but has generally not been known to damage right heart valves or the myocardium, and cardiac fibrosis has not been considered to be a risk if therapy is intermittently interrupted. The woman who is the subject of this case report developed catheterization-proven severe tricuspid and moderate aortic and mitral regurgitation during noncontinuous therapy with methysergide. In addition, right ventricular endomyocardial biopsy revealed extensive endocardial and intramyocardial fibrosis.This publication has 6 references indexed in Scilit:
- Cardiac murmurs and endocardial fibrosis associated with methysergide therapyAmerican Heart Journal, 1974
- Development of heart valve lesions during methysergide therapy.BMJ, 1974
- New instrument for transvenous cardiac biopsyThe American Journal of Cardiology, 1974
- Complications of Methysergide TherapyPublished by American Medical Association (AMA) ,1970
- The cardiac disease associated with the carcinoid syndrome (carcinoid heart disease)The American Journal of Medicine, 1964